Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23842514 | 0.93 | CYP2D6 (0.41) | CYP2D6CYP19A1CYP3A4FAAHLMNA | |
| SCHEMBL15979319 | 0.90 | CYP19A1 (0.37) | CYP2D6CYP19A1CYP3A4FAAHHSP90AA1 | |
| SCHEMBL22964913 | 0.89 | FAAH (0.39) | CYP2D6CYP19A1CYP3A4FAAHLMNA | |
| SCHEMBL18612676 | 0.89 | FAAH (0.39) | CYP2D6CYP19A1CYP3A4FAAHLMNA | |
| SCHEMBL22828519 | 0.87 | FAAH (0.40) | CYP2D6CYP19A1CYP3A4FAAHLMNA | |
| SCHEMBL24871950 | 0.87 | FAAH (0.40) | CYP2D6CYP19A1CYP3A4FAAHLMNA | |
| SCHEMBL24872011 | 0.87 | FAAH (0.40) | CYP2D6CYP19A1CYP3A4FAAHLMNA | |
| SCHEMBL18557088 | 0.87 | FAAH (0.40) | CYP2D6CYP19A1CYP3A4FAAHLMNA | |
| SCHEMBL23842473 | 0.86 | CYP19A1 (0.41) | CYP2D6CYP19A1CYP3A4HSP90AA1 | |
| SCHEMBL18415044 | 0.84 | FAAH (0.38) | CYP2D6CYP19A1CYP3A4FAAHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | CYP2D6 2640/4885CYP19A1 2267/4885CYP3A4 2266/4885 |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | CYP2D6 4461/4885CYP19A1 3245/4885CYP3A4 4560/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | CYP2D6 4461/4885CYP19A1 3245/4885CYP3A4 4560/4885 |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | CYP2D6 2640/4885CYP19A1 2267/4885CYP3A4 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.